References
1. Zinman B., Wanner C., Lachin J.M., et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373 (22): 2117-28.
2. Kulikov A.N., Okovitiy S.V., Ivkin D. Yu. et al. Effects of empagliflozin in an experimental model of chronic heart failure in normoglycemic rats. Serdechnaya nedostatochnost’ [Heart Failure]. 2016; (6): 454-60. (in Russian)
3. Anker S.D., Butler J., Filippatos G., et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation. 2021; 143 (4): 337-49.
4. Anker S.D., Butler J., Filippatos G., et al.; EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019; 21 (10): 1279-87.
5. McMurray J.J.V., Solomon S.D., Inzucchi S.E., et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381 (21): 1995-2008.
6. Karpov A.A., Ivkin D. Yu., Dracheva A.V., et al. Rat model of postinfarct heart failure by left coronary artery occlusion: technical aspects, functional and morphological assessment. Biomeditsina [Biomedicine]. 2014; 1 (3): 32-48. (in Russian)
7. Kazachenko А.А., Okovitiy S.V., Kulikov A.N., et al. Comparative characteristics of some pharmacological models of chronic heart failure. Eksperimental’naya i klinicheskaya farmakologiya [Experimental and Clinical Pharmacology]. 2008; 71 (6): 16-9. (in Russian)
8. Butler J., Usman M.S., Khan M.S., et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020; 7 (6): 3298-309.
9. Martens P., Janssens J., Ramaekers J., et al. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Acta Cardiol. 2020; 75 (3): 211-7.
10. Watanabe K., Ohta Y., Inoue M., et al. Bisoprolol improves survival in rats with heart failure. J Cardiovasc Pharmacol. 2001; 38 (suppl 1): 55-8.
11. Nishio M., Sakata Y., Mano T., et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail. 2008; 10 (5): 446-53.
12. Santos-Gallego C.G., Requena-Ibanez J.A., San Antonio R., et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. JACC Cardiovasc Imaging. 2021; 14 (2): 393-407.
13. Uthman L., Baartscheer A., Bleijlevens B., et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018; 61 (3): 722-6.
14. Thapa S.S., Lal A., Omer A., Trivedi N. Elevated p-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors. J Formos Med Assoc. 2019; 118 (10): 1473-4.
15. Chung Y.J., Park K.C., Tokar S., et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. 2020; 2020: cvaa323.
16. Cappetta D., de Angelis A., Ciuffreda L.P., et al. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol Res. 2020; 157: 104781.